查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576842

Gliclazide市场：按药物类型、剂型、包装、分销管道、患者年龄层、最终用户、应用划分 - 2025-2030 年全球预测

Gliclazide Market by Drug Type (Immediate Release Gliclazide, Modified Release Gliclazide), Formulation (Capsules, Tablets), Dosage Form, Packaging, Distribution Channel, Patient Age Group, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Gliclazide市值为137.2亿美元，预计2024年将达到146.4亿美元，复合年增长率为7.21%，预计到2030年将达到223.5亿美元。

Gliclazide是一种口服降血糖Sulfonylurea，用于透过刺激胰臟β细胞分泌胰岛素来治疗第二型糖尿病。这种需求是由于糖尿病盛行率不断增加，需要有效的血糖控制方案来预防併发症。Gliclazide适应症广泛，主要针对中老年第2型糖尿病患者，常与饮食、运动疗法等生活方式介入结合使用。最终用途范围主要包括可以很好地管理处方和监测的医院、诊所和门诊病人场所。Gliclazide市场的开拓是由糖尿病盛行率上升、认识提高以及对有效且负担得起的糖尿病管理的需求所推动的，特别是在糖尿病负担日益增加的新兴市场。机会在于扩大新兴市场的可及性、利用数位健康平台进行监测以及整合多学科方法进行糖尿病护理，包括Gliclazide。然而，低血糖等潜在副作用、新型糖尿病药物的竞争以及患者依从性的需求等挑战可能会阻碍成长。限制也来自于精确剂量个体化的需要，这可能使治疗方法变得复杂。患者教育、联合治疗和个人化医疗等领域的创新可能会进一步推动市场渗透。长期给药（例如缓释性）和新型递送系统的研究可能会改善治疗结果。了解市场动态突显了竞争格局，需要专注于成本效益、监管挑战以及适应快速的技术进步。为了利用市场机会，公司应该投资新配方的研发，透过策略伙伴关係增加市场占有率，并将行销力度集中在糖尿病人口快速成长的新兴国家。

主要市场统计
基准年[2023] 137.2亿美元
预测年份 [2024] 146.4亿美元
预测年份 [2030] 223.5亿美元
复合年增长率（%） 7.21%

市场动态：揭示快速发展的Gliclazide市场的关键市场洞察

供需的动态交互作用正在改变Gliclazide市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于不健康的饮食和久坐的生活方式，肥胖人口不断增加
    • 增加对医疗卫生基础设施和医疗设施的投资
  • 市场限制因素
    • 市面上替代疗法的可用性
  • 市场机会
    • 增加研发和医疗基础建设的投资
    • 糖尿病治疗药物个别化的进展
  • 市场挑战
    • 严格的法规环境导致核准流程冗长

波特五力：驾驭Gliclazide市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Gliclazide市场的外部影响

外部宏观环境因素对Gliclazide市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解Gliclazide市场竞争状况

对Gliclazide市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵Gliclazide市场供应商的绩效评估

FPNV定位矩阵是评估Gliclazide市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了Gliclazide市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，Gliclazide市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 不健康的饮食习惯和久坐的生活方式相结合导致肥胖人数的增加。
      • 增加对医疗卫生基础设施和医疗设施的投资
    • 抑制因素
      • 市面上替代治疗方法的可用性
    • 机会
      • 增加研发和医疗基础建设的投资
      • 糖尿病药物个体化的进展
    • 任务
      • 严格的法规环境减缓了核准流程
  • 市场区隔分析
    • 药物类型：由于血糖控制时间更长且更一致，因此越来越多地采用缓释性药物Gliclazide
    • 最终用户：有效管理急性病例的快速反应提高了医院的采用率
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章Gliclazide市场药物按类型

  • 即时释Gliclazide
  • 改良释放Gliclazide

第七章Gliclazide处方市场

  • 胶囊
  • 药片

第八章Gliclazide剂型市场

  • 联合治疗
  • 单一疗法

第九章Gliclazide市场：依包装分类

  • 泡壳包装
  • 瓶子
  • 小袋

第10章Gliclazide市场：按分销管道

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第十一章按患者年龄组别分類的Gliclazide市场

  • 成人用
  • 老年病
  • 小儿科

第十二章Gliclazide市场：依最终用户分类

  • 居家护理
  • 医院
  • 专科诊所

第十三章Gliclazide市场：依应用分类

  • 血糖控制
  • 对心血管的好处
  • 改善胰岛素敏感性

第十四章Gliclazide美洲市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十五章 亚太地区Gliclazide市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十六章 欧洲、中东和非洲Gliclazide市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十七章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Endogenex 已获得 8,800 万美元的 C 系列资金筹措，以推进创新 2 型糖尿病治疗的重要 ReCET 研究。
  • 战略分析和建议
Product Code: MRR-81515600A44D

The Gliclazide Market was valued at USD 13.72 billion in 2023, expected to reach USD 14.64 billion in 2024, and is projected to grow at a CAGR of 7.21%, to USD 22.35 billion by 2030.

Gliclazide is an oral hypoglycemic sulfonylurea class medication used to manage type 2 diabetes by stimulating insulin secretion from pancreatic beta cells. Its necessity stems from the growing prevalence of diabetes, which calls for effective glycemic control options to prevent complications. The application of gliclazide extends to a wide demographic, primarily targeting middle-aged and elderly individuals with type 2 diabetes, and is often combined with lifestyle interventions like diet and exercise. The end-use scope predominantly involves hospitals, clinics, and outpatient care settings, where prescription and monitoring can be adequately managed. Market growth for gliclazide is driven by rising diabetes prevalence, increased awareness, and the demand for effective and affordable diabetes management, especially in developing regions where the burden of diabetes is increasing. Opportunities lie in expanding accessibility in emerging markets, leveraging digital health platforms for monitoring, and integrating multi-disciplinary approaches to diabetes care that include gliclazide. However, challenges such as potential side effects like hypoglycemia, competition from newer classes of diabetes medications, and the necessity of patient compliance can hinder growth. Limitations also arise from the requirement of precise dosage personalizations, which can complicate treatment regimens. Innovating in areas such as patient education, combination therapies, and personalized medicine can propel further market penetration. Research into prolonged or novel delivery systems, like controlled-release formulations, could enhance therapeutic outcomes. Understanding the market dynamics highlights a competitive landscape, with a need to focus on cost-effectiveness, regulatory challenges, and adaptation to rapid technological advancements. To capitalize on market opportunities, companies should invest in R&D for novel formulations, enhance market presence through strategic partnerships, and emphasize marketing efforts on emerging economies with burgeoning diabetic populations.

KEY MARKET STATISTICS
Base Year [2023] USD 13.72 billion
Estimated Year [2024] USD 14.64 billion
Forecast Year [2030] USD 22.35 billion
CAGR (%) 7.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gliclazide Market

The Gliclazide Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing obese population coupled with unhealthy diets and sedentary lifestyles
    • Rising investments in healthcare infrastructure and medical facilities
  • Market Restraints
    • Availability of alternative treatments in the market
  • Market Opportunities
    • Rising investment in R&D and healthcare infrastructure development
    • Advancements in personalize diabetic medications
  • Market Challenges
    • Stringent regulatory environment leading to time-consuming approval process

Porter's Five Forces: A Strategic Tool for Navigating the Gliclazide Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gliclazide Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gliclazide Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gliclazide Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gliclazide Market

A detailed market share analysis in the Gliclazide Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gliclazide Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gliclazide Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gliclazide Market

A strategic analysis of the Gliclazide Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gliclazide Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., Biocon, Cipla, Dr. Reddy's Laboratories, Kavya Pharma, Kreative Organics, Lexicare Pharma Private Limited, Lupin Pharmaceuticals, Mankind Pharma, MANUS AKTTEVA BIOPHARMA LLP, Sanify Healthcare, Shobha Life Sciences, Supra Chemicals, Torrent Pharmaceuticals, Wellona Pharma, and Zeelab Pharmacy Private Limited.

Market Segmentation & Coverage

This research report categorizes the Gliclazide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Immediate Release Gliclazide and Modified Release Gliclazide.
  • Based on Formulation, market is studied across Capsules and Tablets.
  • Based on Dosage Form, market is studied across Combination Therapy and Monotherapy.
  • Based on Packaging, market is studied across Blister Packs, Bottles, and Pouches.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Application, market is studied across Blood Sugar Control, Cardiovascular Benefits, and Insulin Sensitivity Improvement.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing obese population coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.2. Rising investments in healthcare infrastructure and medical facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative treatments in the market
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment in R&D and healthcare infrastructure development
      • 5.1.3.2. Advancements in personalize diabetic medications
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment leading to time-consuming approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug type: Increasing adoption of modified release gliclazide due to more extended and consistent blood glucose control
    • 5.2.2. End-User: Increasing adoption in hospitals due to rapid onset of action to manage acute cases effectively
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gliclazide Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Immediate Release Gliclazide
  • 6.3. Modified Release Gliclazide

7. Gliclazide Market, by Formulation

  • 7.1. Introduction
  • 7.2. Capsules
  • 7.3. Tablets

8. Gliclazide Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Monotherapy

9. Gliclazide Market, by Packaging

  • 9.1. Introduction
  • 9.2. Blister Packs
  • 9.3. Bottles
  • 9.4. Pouches

10. Gliclazide Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Drug Stores
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Retail Pharmacies

11. Gliclazide Market, by Patient Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Gliclazide Market, by End-User

  • 12.1. Introduction
  • 12.2. Homecare
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Gliclazide Market, by Application

  • 13.1. Introduction
  • 13.2. Blood Sugar Control
  • 13.3. Cardiovascular Benefits
  • 13.4. Insulin Sensitivity Improvement

14. Americas Gliclazide Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Gliclazide Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Gliclazide Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. Endogenex secures eighty-eight million dollars in Series C funding to advance pivotal ReCET study for innovative type 2 diabetes treatment
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Anant Pharmaceuticals Pvt. Ltd.
  • 3. Apotex Inc.
  • 4. Biocon
  • 5. Cipla
  • 6. Dr. Reddy's Laboratories
  • 7. Kavya Pharma
  • 8. Kreative Organics
  • 9. Lexicare Pharma Private Limited
  • 10. Lupin Pharmaceuticals
  • 11. Mankind Pharma
  • 12. MANUS AKTTEVA BIOPHARMA LLP
  • 13. Sanify Healthcare
  • 14. Shobha Life Sciences
  • 15. Supra Chemicals
  • 16. Torrent Pharmaceuticals
  • 17. Wellona Pharma
  • 18. Zeelab Pharmacy Private Limited

LIST OF FIGURES

  • FIGURE 1. GLICLAZIDE MARKET RESEARCH PROCESS
  • FIGURE 2. GLICLAZIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLICLAZIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLICLAZIDE MARKET DYNAMICS
  • TABLE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY IMMEDIATE RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY MODIFIED RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY POUCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLICLAZIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLICLAZIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GLICLAZIDE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GLICLAZIDE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GLICLAZIDE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GLICLAZIDE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GLICLAZIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GLICLAZIDE MARKET SIZE, BY BLOOD SUGAR CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GLICLAZIDE MARKET SIZE, BY CARDIOVASCULAR BENEFITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GLICLAZIDE MARKET SIZE, BY INSULIN SENSITIVITY IMPROVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. POLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. QATAR GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. RUSSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. SPAIN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. SWEDEN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. SWEDEN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 331. SWEDEN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SWITZERLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 345. TURKEY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. TURKEY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 347. TURKEY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 353. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 369. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 370. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023